September, 11 2014

Inlacin, a product from Dexa Laboratories of Biomolecular Sciences (DLBS), was discussed at the 8th Diabetes, Obesity, and Cardiovascular Link 2014 (DOC Link 2014) Symposium held by the Indonesian Society of Endocrinology (PERKENI).

Through a paper titled "Insulin Resistance Management Update (DLBS3233)", Prof. Sidartawan Soegondo Sp. PD, KEMD, FACE explained the advantages of Inlacin in treating patients with diabetes.

With so many diabetes drugs, doctors are required to keep learning about diabetes treatment guidelines from within and outside the country, said Prof. Sidartawan in the event held in the Ballroom of Novotel Hotel Mangga Dua Square, Jakarta, on Saturday, August 30, 2014.

Although these guidelines from the diabetes experts was considered as advice and guidance, it doesn't have to be strictly followed as an algorithm or part of a prescription, and should be combined with the clinical condition of the patient.

Prof. Sidartawan also reminding that there's already a diabetes drug produced by an Indonesian company, which is Inlacin. "Inlacin is categorized as an insulin sensitizer that was developed in the Dexa Medica laboratory," said Prof. Sidartawan.

Inlacin's effects are inhibiting Serine Phosphorylation, reducing TNF Alpha, reducing FFA, and increasing insulin sensitivity. In the three years since it was produced, Inlacin was entered into the list of prescribed drugs such as: Acarbose, Glinides, Metformin Sulfonylurea, Glitazone, and Incretin. Prof. Sidartawan also said that this drug doesn't have side effects.

Research on Inlacin has also been done by Indonesian diabetes experts, namely: Prof. Dr. dr. Ketut Suastika, SpPD-KEMD (Denpasar), Prof. Dr. dr. Karel Pandelaki, SpPD-KEMD (Manado), Prof. Dr. dr. H. Asman Manaf, SpPD-KEMD (Padang), and Prof. Dr. dr. Askandar Tjokroprawiro, SpPD-KEMD (Surabaya).

Inlacin is composed of Bioactive Fraction DLBS3233, with indication to reduce blood glucose level. The dosage is 50 mg or 100 mg a day for monotherapy or combined therapy. Corporate communications